Cooperative Agreement NU27DD001153

This $500,000 Project Grant award from the U.S. Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program supports research to improve understanding of delayed diagnosis of venous thromboembolism (VTE) in ambulatory care settings. The project aims to leverage electronic health record (EHR) data and stakeholder expertise to identify risk factors, disparities, and outcomes associated with delayed and missed VTE diagnosis in...

This $151,523 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research by The Medical College of Wisconsin, Inc. to investigate the role of the protein fibrinogen in regulating inflammatory and clotting processes associated with acute and chronic venous thrombosis (blood clots). The research will utilize novel RNA therapy delivered via lipid nanoparticles to selectively reduce...

This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on...

This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine the role of the PAR1/IL-17 signaling axis in the development and progression of chronic thromboembolic pulmonary hypertension (CTEPH). The $723,084 award to the University of Colorado-Denver aims to: 1) Assess whether PAR1/IL-17 signaling synergistically promotes abnormal phenotypes in cells derived from CTEPH...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $234,000.00 to the University of Colorado-Denver to engineer "hemostatic red blood cells" (T-RBCs) capable of adhering to collagen and fibrin clots. The goal is to develop a novel therapeutic approach to slow or stop non-compressible hemorrhage, which is a major cause of...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to define the role of platelet ABO(H) blood group antigens in hemostasis (blood clotting) and thrombosis (blood clotting disorders). The $445,708 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will fund research with the following objectives: Determine the impact of ABO(H) glycans on...

This federal Project Grant award from the National Science Foundation's Division of Civil, Mechanical, and Manufacturing Innovation (CFDA 47.041 - Engineering) provides $500,000 in funding to North Carolina State University to conduct fundamental research aimed at reducing blood clotting in medical devices. The key products and services to be delivered under this award include: 1) molecular dynamics simulations and interfacial spectroscopy to understand the role of hydration layers in preventing...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $666,710 to The Johns Hopkins University to conduct research on the role of the BCL6 co-repressor (BCOR) in regulating coagulation factor VII and its impact on venous thromboembolism (VTE) risk. The key objectives are to: (1) characterize how BCOR suppresses factor VII expression through epigenetic regulators PRC1.1 and ATAC,...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $779,952 to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to conduct research on the role of platelets in remote organ injury and infection following ischemic stroke. The key objectives are to: (1) elucidate how activated platelets contribute to remote organ injury and infection after...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $764,817 to the University of North Carolina at Chapel Hill to conduct research on the mechanisms of coagulopathy and bleeding in acute promyelocytic leukemia (APL). The study aims to determine the individual contributions of the podoplanin-CLEC-2 pathway, the S100/Annexin A2/tissue plasminogen activator and the urokinase-type plasminogen...